Joo-Won Hong
Research Subjects
Joo-Won Hong has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ga Won Kim2 shared publications
- Hyo-Eun Lee
Aquatic Disease Control Division, National Fisheries Products Quality Management Service, 216 Gijanghaean-ro, Gijang-eup, Gijang-gun, Busan 46083, Republic of Korea
2 shared publications - Ji-Hoon Lee
Department of Aquatic Life Medicine, Kunsan National University, Gunsan, Republic of Korea
2 shared publications - Jung Soo Seo2 shared publications
- Mun-Gyeong Kwon
Aquatic Disease Control Division, National Fishery Products Quality Management Service, Busan 46083, Korea
2 shared publications Kim Youngsook
1 shared publication
Latest Publications
- Open Access
- 30 September 2026
- Published by The Korean Society of Fisheries and Aquatic Science in Fisheries and Aquatic Sciences
- Vol. 29 (9) , 612-621
Tissue recovery and amoxicillin residue depletion at alternative injection sites in olive flounder (Paralichthys olivaceus)
Fisheries and Aquatic Sciences
- 30 September 2026
- Published by The Korean Society of Fisheries and Aquatic Science in Fisheries and Aquatic Sciences
- Vol. 29 (9) , 612-621
Open AccessTissue recovery and amoxicillin residue depletion at alternative injection sites in olive flounder (Paralichthys olivaceus)
Fisheries and Aquatic Sciences
- Open Access
- 15 April 2026
- Published by Elsevier in SSRN Electronic Journal
Site and Temperature Dependent Pharmacokinetics, Pharmacodynamics, and Withdrawal Time of Ceftiofur in Olive Flounder (Paralichthys olivaceus)
This study aimed to identify alternative intramuscular injection sites for ceftiofur in olive flounder (Paralichthys olivaceus) that maintain therapeutic efficacy and residue compliance while mitigating injection-site lesions in the edible dorsal fillet, which can reduce consumer acceptance despite short regulatory withdrawal periods. Following a single 10 mg/kg dose at four sites (dorsal, tail, cheek, pectoral fin) under two temperatures (23 °C, 13 °C), HPLC–MS/MS quantified exposure and residue depletion; PK/PD indices and withdrawal times were integrated with histopathology. %T>MIC exceeded β-lactam thresholds in most conditions, with the exception of pectoral fin at 13 °C (32.7% assuming MIC = 1 µg/mL). Dorsal injection at 23 °C met the 7-day withdrawal period, whereas non-dorsal sites exceeded this limit at the 99% tolerance level. Histopathology revealed lesions persisting to 168 h post-injection at all sites, underscoring marketability concerns for edible fillet. Collectively, tail muscle demonstrated relatively stable pharmacokinetics across temperatures and may represent a viable alternative injection site; however, an extended withdrawal period beyond the currently approved 7 days would be required for regulatory compliance at 23 °C. Dorsal injection provides the best balance of efficacy and regulatory compliance. These findings support site-specific dosing guidance to optimize outcomes and consumer acceptance.
- 15 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSite and Temperature Dependent Pharmacokinetics, Pharmacodynamics, and Withdrawal Time of Ceftiofur in Olive Flounder (Paralichthys olivaceus)
This study aimed to identify alternative intramuscular injection sites for ceftiofur in olive flounder (Paralichthys olivaceus) that maintain therapeutic efficacy and residue compliance while mitigating injection-site lesions in the edible dorsal fillet, which can reduce consumer acceptance despite short regulatory withdrawal periods. Following a single 10 mg/kg dose at four sites (dorsal, tail, cheek, pectoral fin) under two temperatures (23 °C, 13 °C), HPLC–MS/MS quantified exposure and residue depletion; PK/PD indices and withdrawal times were integrated with histopathology. %T>MIC exceeded β-lactam thresholds in most conditions, with the exception of pectoral fin at 13 °C (32.7% assuming MIC = 1 µg/mL). Dorsal injection at 23 °C met the 7-day withdrawal period, whereas non-dorsal sites exceeded this limit at the 99% tolerance level. Histopathology revealed lesions persisting to 168 h post-injection at all sites, underscoring marketability concerns for edible fillet. Collectively, tail muscle demonstrated relatively stable pharmacokinetics across temperatures and may represent a viable alternative injection site; however, an extended withdrawal period beyond the currently approved 7 days would be required for regulatory compliance at 23 °C. Dorsal injection provides the best balance of efficacy and regulatory compliance. These findings support site-specific dosing guidance to optimize outcomes and consumer acceptance.